Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT07108699 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: HSK39004 Dry Powder Inhaler-0.75mg
DRUG: HSK39004 Dry Powder Inhaler-1.5mg
DRUG: HSK39004 Dry Powder Inhaler Simulant

Sponsor

Haisco Pharmaceutical Group Co., Ltd.